文章：

蛋白激酶抑制剂在难治性小细胞肺癌中的应用前景：现状与未来展望

Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities

原文发布日期：27 February 2024

DOI: 10.3390/cancers16050963

类型: Article

开放获取: 是

英文摘要：

SCLC is refractory to conventional therapies; targeted therapies and immunological checkpoint inhibitor (ICI) molecules have prolonged survival only marginally. In addition, ICIs help only a subgroup of SCLC patients. Different types of kinases play pivotal roles in therapeutics-driven cellular functions. Therefore, there is a significant need to understand the roles of kinases in regulating therapeutic responses, acknowledge the existing knowledge gaps, and discuss future directions for improved therapeutics for recalcitrant SCLC. Here, we extensively review the effect of dysregulated kinases in SCLC. We further discuss the pharmacological inhibitors of kinases used in targeted therapies for recalcitrant SCLC. We also describe the role of kinases in the ICI-mediated activation of antitumor immune responses. Finally, we summarize the clinical trials evaluating the potential of kinase inhibitors and ICIs. This review overviews dysregulated kinases in SCLC and summarizes their potential as targeted therapeutic agents. We also discuss their clinical efficacy in enhancing anticancer responses mediated by ICIs.

摘要翻译： 

小细胞肺癌对常规疗法具有难治性；靶向治疗和免疫检查点抑制剂分子仅能略微延长生存期。此外，免疫检查点抑制剂仅对部分小细胞肺癌患者有效。不同类型的激酶在治疗驱动的细胞功能中发挥着关键作用。因此，亟需理解激酶在调节治疗反应中的作用，认识现有知识空白，并探讨改善难治性小细胞肺癌治疗的未来方向。本文系统综述了激酶失调在小细胞肺癌中的影响，进一步讨论了用于难治性小细胞肺癌靶向治疗的激酶药理抑制剂，同时阐述了激酶在免疫检查点抑制剂介导的抗肿瘤免疫应答激活中的作用。最后，总结了评估激酶抑制剂与免疫检查点抑制剂潜力的临床试验。本综述概述了小细胞肺癌中失调的激酶，并总结了其作为靶向治疗药物的潜力，同时探讨了其在增强免疫检查点抑制剂介导的抗癌反应中的临床疗效。

原文链接：

Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities